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Maillard or browning reactions between reducing
sugars and protein lead to formation of advanced glyca-
tion end products (AGEs) and are thought to contribute
to the pathogenesis of diabetic complications. AGE in-
hibitors such as aminoguanidine and pyridoxamine
(PM) inhibit both the formation of AGEs and develop-
ment of complications in animal models of diabetes. PM
also inhibits the chemical modification of protein by
advanced lipoxidation end products (ALEs) during lipid
peroxidation reactions in vitro. We show here that sev-
eral PM adducts, formed in incubations of PM with lino-
leate and arachidonate in vitro, are also excreted in the
urine of PM-treated animals. The PM adducts N-non-
anedioyl-PM (derived from linoleate), N-pentanedioyl-
PM, N-pyrrolo-PM, and N-(2-formyl)-pyrrolo-PM (de-
rived from arachidonate), and N-formyl-PM and
N-hexanoyl-PM (derived from both fatty acids) were
quantified by liquid chromatography-mass spectrome-
try analysis of rat urine. Levels of these adducts were
increased 5–10-fold in the urine of PM-treated diabetic
and hyperlipidemic rats, compared with control ani-
mals. We conclude that the PM functions, at least in
part, by trapping intermediates in AGE/ALE formation
and propose a mechanism for PM inhibition of AGE/ALE
formation involving cleavage of -dicarbonyl intermedi-
ates in glycoxidation and lipoxidation reactions. We also
conclude that ALEs derived from polyunsaturated fatty
acids are increased in diabetes and hyperlipidemia and
may contribute to development of long term renal and
vascular pathology in these diseases.
Non-enzymatic chemical modification of protein by reducing
sugars, known as the Maillard reaction, is implicated in the
development of pathology during aging and in chronic diseases
such as diabetes, atherosclerosis, and Alzheimers disease (1–
3). The Maillard reaction between sugar and protein proceeds
through a labile Schiff base, which isomerizes to a ketoamine
adduct, the Amadori compound. Oxidative decomposition and
further reaction of the Amadori compound produce advanced
glycation end products (AGEs),1 such as pentosidine and
vesperlysines (2). Similarly, advanced lipoxidation end prod-
ucts (ALEs), such as the malondialdehyde and 4-hydroxy-2-
nonenal adducts to lysine, are formed on protein during lipid
peroxidation reactions (4, 5).N-(Carboxymethyl)lysine andN-
(carboxyethyl)lysine, which are major products of both glycoxi-
dation and lipoxidation reactions (4–6), are termed AGE/ALEs.
Through effects on protein structure, function, and turnover,
the accumulation of AGEs and ALEs in tissue proteins is
thought to contribute to the development of diabetic
complications.
AGE/ALE inhibitors are designed to limit the accumulation
of AGE/ALEs in protein and thereby protect against the devel-
opment of diabetic complications. Hudson and colleagues (7–9)
reported that PM was a potent inhibitor of the formation of
AGEs from Amadori adducts in vitro. Onorato et al. (10) later
reported that PM traps intermediates in lipid peroxidation and
protects proteins from chemical modification during lipid per-
oxidation reactions (lipoxidation) in vitro. Degenhardt et al.
(11) and Alderson et al. (12) demonstrated that PM also inhib-
ited the formation of AGE/ALEs in vivo and retarded the de-
velopment of nephropathy in both streptozocin (STZ)-induced
diabetic and Zucker (obese, hyperlipidemic) rats. The presence
of severe hyperlipidemia in the STZ diabetic rats and the
reno-protective effects of PM in both the diabetic and the
Zucker rat suggested that lipids, rather than carbohydrates,
might be the primary source of chemical modification of pro-
teins in diabetes.
In the present study, we have extended earlier work on the
reaction of PM with the polyunsaturated fatty acids (PUFAs),
linoleate and arachidonate, to identify other intermediates
trapped by PM during lipid peroxidation reactions and to de-
termine whether PM functions as an inhibitor of advanced
lipoxidation reactions in vivo. We show that several lipid-de-
rived PM adducts formed in in vitro reactions are also detected
in the urine of PM-treated control, diabetic, and hyperlipidemic
rats and that these adducts are present at substantially higher
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(DK-19971). The costs of publication of this article were defrayed in part
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concentrations in the urine of diabetic and hyperlipidemic an-
imals, compared with control rats. Our results support a role
for lipoxidation reactions in the chemical modification of pro-
teins and development of complications in diabetes and pre-
diabetic hyperlipidemic states and demonstrate that the pro-
tective effects of PM are consistent with its role in reducing
plasma lipids and trapping intermediates in lipoxidation reac-
tions in vivo.
EXPERIMENTAL PROCEDURES
Materials—Except where indicated, all chemicals were purchased
from Sigma-Aldrich or Fisher Scientific.
Reaction of PM with Fatty Acids—PM (1 mM) and either linoleic acid
(LA) (5 mM) or arachidonic acid (AA) (5 mM) were incubated in 200 mM
phosphate buffer, pH 7.4, in a shaking water bath at 37 °C, and phos-
phate buffers were sterilized by ultrafiltration through 0.2-m syringe
filters (Costar Corp., Acton, MA). Aliquots were taken at 0, 1, 3, and 6
days, quenched with a final concentration of 1 mM diethylenetriamine-
pentaacetic acid, and frozen at 70 °C until analyzed. Samples were
diluted 1:10 in 0.1% heptafluorobutyric acid (HFBA) (Acros Organics,
Morris Plains, NJ) before analysis by reversed phase high performance
liquid chromatography (RP-HPLC) and/or positive ion electrospray ion-
ization liquid chromatography/mass spectrometry/mass spectrometry
(ESI-LC/MS/MS). Control incubations consisted of either PM or PUFA
alone.
Synthesis of PM Adducts—All synthesized PM adduct standards
were purified by RP-HPLC and characterized by ESI-LC/MS/MS
and/or by 1H and 13C NMR, as described below. The structures of
synthesized PM adducts that were also detected in urine are shown in
Fig. 1.
N-Hexanoyl-PM (HAPM) and N-nonanedioyl-PM (NDAPM) were
synthesized from PM and hexanoyl chloride or nonanedioic acid
monomethyl ester, respectively, as described (10). For ESI-MS of
HAPM, m/z  267 [MH], and for NDAPM, m/z  339 [MH].
Heavy labeled N-hexanoyl-PM (d11-HAPM) was synthesized from
PM(HCl)2 and d11-hexanoic acid according to the method of Kato et al.
(13). Equimolar amounts (0.6 mmol) of d11-hexanoic acid (Cambridge
Isotope Laboratories, Inc., Andover, MA), 1-ethyl-3-(3-dimethylamin-
opropyl)carbodiimide hydrochloride, and N-hydroxysulfosuccinimide
(Pierce) were dissolved in 15 ml of dimethylformamide and incubated
for 24 h at room temperature. PM(HCl)2 (0.6 mmol) in 1 ml of 200 mM
borate buffer, pH 9, was added, and the reaction mixture was incubated
for an additional 4 h. The reaction mixture was diluted to 30 ml with
water, and the pH was adjusted to 8.1 with 1 M NaOH. The mixture was
extracted three times with an equal volume of diethyl ether, and the
pooled extracts were dried under nitrogen. The resulting white powder
was reconstituted in 1% HFBA, and d11-HAPM was purified in 20%
yield by semi-preparative RP-HPLC. For ESI-MS,m/z 278 [MH].
N-Pentanedioyl-PM (PDAPM) was synthesized from PM and glutaric
anhydride. PM(HCl2) (0.24 mg; 1 mol) was dissolved in 1 ml of 250 mM
NaHCO3, pH 10, and placed in a shaking water bath at 37 °C. A total of
3.4 mg (30 mol) of glutaric anhydride was added in three aliquots at
10-min intervals, and the reaction was continued for an additional 10
min after the last addition. The reaction mixture was then dried over-
night in vacuo (Savant Speed Vac, Savant Instruments Inc., Farming-
dale, NY). The residue was reconstituted in 1%HFBA, and PDAPMwas
purified (20% yield) by semi-preparative RP-HPLC. For ESI-MS,
m/z  283 [MH].
N-Formyl-PM (FAPM) was synthesized according to the method of
Yamada and Okamoto (14). Briefly, pyridoxineHCl (1.14 g, 10 mmol)
was added to 4.8 ml of formamide (120 mmol) and incubated in a
heating block at 100 °C for 24 h. The resulting red oil was diluted 1:100
in 1% HFBA, and a red precipitate formed immediately and was re-
moved by centrifugation. The supernatant was fractionated by RP-
HPLC, and a region containing FAPM was collected and dried over-
night in vacuo. FAPM was subsequently purified in 50% yield upon
re-injection of the collected fraction. For ESI-MS, m/z  197 [MH].
Structure conformation was provided by 1H NMR on a Varian (Palo
Alto, CA) Inova 500 MHz instrument using deuterated dimethyl sulf-
oxide (d6-Me2SO) as solvent. The chemical shifts were:  2.49 (s, 3H),
4.37 (d, 2H, J  5.8 Hz), 4.72 (s, 2H), 5.20 (s, 1H), 5.75 (s, 1H), 8.01 (s,
1H), 8.92 (t, 1H, J  5.8 Hz), and 11.2 (s, 1H).
N-Pyrrolo-PM (PyPM) was synthesized by the method of D’Silva and
Walker (15). Briefly, PM(HCl)2 (0.27 g, 1 mmol) and 2,5-dimethoxytet-
rahydrofuran (0.16 g, 1 mmol) were dissolved in 4.25 ml of pyridine:
acetic acid:water (1.9:1.35:1), and the mixture was reacted in a heating
block at 100 °C for 2 h. The resulting brown liquid was diluted 1:100 in
1% HFBA, and PyPM was purified in 95% yield by semi-preparative
RP-HPLC. For ESI-MS, m/z  219 [MH]. Structure conformation
was provided by 500 MHz 1H and 13C NMR using d6-Me2SO as solvent.
The chemical shifts were: 1H NMR  2.60 (s, 3H), 4.55 (s, 2H), 5.30 (s,
2H), 5.97 (s, 2H), 6.75 (s, 2H), and 8.20 (s, 1H). The chemical shifts were:
13C NMR  15.8 [–CH3 (PM)], 42.3 [–CH2– (PM)], 57.5 [–CH2– (PM)],
107.9 [–CH(pyrrole)], 121.2 [–CH(pyrrole)], and 130.6–152.2 [5 pyr-
idinyl (PM)].
N-(2-Formyl)-pyrrolo-PM (FPyPM) was synthesized from PM and
xylose based on the method of Hayase and Kato (16). PM(HCl)2 (2.4 g,
10 mmol) and xylose (1.5 g, 10 mmol) were dissolved in 5 ml of water
and heated at 95 °C for 2 h, after adjusting the pH to 4 with 6 N NaOH.
The resulting brown liquid was extracted three times with equal vol-
umes of diethyl ether, and the pooled ether extracts were evaporated
under nitrogen. The residue was reconstituted in 1% HFBA, and
FPyPM was purified in 0.1% yield by semi-preparative RP-HPLC. For
ESI-MS, m/z  247 [MH]. Structure conformation was provided by
500 MHz 1H NMR using d6-Me2SO as a solvent. The chemical shifts
were:  2.35 (s, 3H), 4.38 (d, 2H, J  4.7 Hz), 5.20 (t, 1H, J  4.7 Hz),
5.60 (s, 2H), 6.15 (dd, 1H, J  2.5, 3.9 Hz), 6.82 (unresolved dd, 1H),
7.00 (dd, 1H, J  1.7, 3.9 Hz), 7.99 (s, 1H), and 9.61 (s, 1H).
Quantification of PM Adduct Standards—The concentrations of
FAPM, HAPM, NDAPM, and PDAPM standards were determined by
acid hydrolysis and subsequent quantification of released PM, as de-
scribed (10). Briefly, aliquots of standard were hydrolyzed in 2 N HCl for
2 h at 95 °C, dried in vacuo, and then reconstituted in 1% HFBA. The
concentrations of standards were determined, based on the yield of PM
measured by RP-HPLC.
Because FPyPM and PyPMwere stable to acid hydrolysis and did not
exhibit the fluorescence characteristic of compounds containing PM, the
concentrations of these standards were determined by RP-HPLC using
FIG. 1. PM adducts identified in reactions of PM with oxidiz-
ing PUFA and in the urine of animals treated with PM. HAPM
and FAPM are found in reactions of PM with either LA or AA reactions.
PDAPM, FPyPM, and PyPM are found only in the AA incubation,
whereas NDAPM is unique to the LA system.
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absorbance detection as described below. FPyPM and PyPM concentra-
tions were estimated using the molar extinction coefficient of PM
(92,000 M1 cm1).
RP-HPLC—Samples were analyzed on a Waters (Milford, MA) 626/
600 HPLC system, using an Aquasil (Thermo Hypersil-Keystone, Belle-
fonte, PA) C-18 column (5 m; 250 mm  4.6 mm) at a flow rate of 0.95
ml/min. Solvent A was 0.1% HFBA in water and Solvent B was 90%
acetonitrile in water. The gradient was as follows: 0–2 min, 15% B;
2–37 min, linear ramp to 90% B; 37–40 min, hold at 90% B; 40–50 min,
return to 15% B; 50–65 min, hold at 15% B. PM and PM adducts were
detected by fluorescence (ex  295 nm, em  393 nm) and/or by
absorbance at 294 nm.
Mass Spectrometry—ESI-LC/MS/MS was performed on a Micro-
mass (Beverly, MA) Quattro LC mass spectrometer equipped with an
Agilent (Palo Alto, CA) 1100 series HPLC system and an Aquasil C-18
column (5 m, 250  2 mm) at a flow rate of 0.2 ml/min. Solvent A was
0.1% HFBA in water and Solvent B was 90% acetonitrile in water; all
solvents including water were of HPLC grade. The gradient was as
follows: 0–5 min, 15% B; 5–37 min, linear ramp to 90% B; 37–42 min,
hold at 90% B; 42–52 min, return to 15% B; 52–60 min, hold at 15% B.
The capillary was held at 3.11 kV, and the sampling cone and collision
cell were held at 14 and 20 V, respectively. The source block and
desolvation temperatures were maintained at 100 and 350 °C,
respectively.
The identity of all synthesized PM adducts detected in urine was
unequivocally established by mixing experiments and by ESI-LC/MS/
MS, including precursor-ion and product-ion spectrum scans. PM and
PM adducts generate m/z  152 as the predominant product-ion, cor-
responding to the deaminated ion (PM), deamidated ion (FAPM,
HAPM, NDAPM, and PDAPM), or loss of the pyrrole functional group
(FPyPM and PyPM), when subjected to collision-induced dissociation.
In addition to m/z  152, unidentified intramolecular rearrangement
ions of PM (m/z  140 and 134) were consistently observed in product-
ion analyses of all PM adducts, as well as the [MH] ion of PM,m/z 
169.
Animal Studies—All studies were carried out in accordance with the
guidelines of the Institutional Animal Care and Use Committee of the
University of South Carolina. Female Sprague-Dawley rats were pur-
chased at 5 weeks of age from Harlan Industries (Indianapolis, IN).
Male Zucker diabetic fatty (ZDF/Gmi-fa), lean Zucker diabetic fatty
(/fa), and Zucker non-diabetic fatty (fa/fa) rats were purchased at 5
weeks of age from Genetic Models, Inc. (Charles River Laboratories,
Wilmington, MA). Rats were housed in the Animal Resource Facility for
1 week before studies were started; all animals had free access to food
and water throughout the study. Plasma glucose and plasma triglycer-
ides were measured with Sigma Kit No. 315 and No. 339, respectively.
Sprague-Dawley rats were maintained on Harlan Teklad (Indianap-
olis, IN) rodent diet (W). Diabetes was induced by a single tail-vein
injection of 45 mg/kg streptozocin in 0.1 M sodium citrate buffer, pH 4.5,
as described previously (11). Non-diabetic animals were sham-injected
with buffer only. Animals with plasma glucose above 16 mM were
classified as diabetic and assigned to either an untreated diabetic
control group (STZ-Db, n  16) or a diabetic group receiving PM (STZ-
DbPM, n 16) in drinking water at 1 g/liter. Non-Db (n 12) animals
received PM (non-DbPM) in drinking water at 2 g/liter, to compen-
sate, in part, for the lower water consumption of these animals. Diabetic
animals received insulin (3–5 IU; Humulin; Eli Lilly, Indianapolis, IN)
3 times/week to maintain body weight and limit hyperglycemia. Plasma
glucose in STZ-Db animals was 25 mM throughout the study, whereas
plasma glucose in non-Db animals remained at 5 mM. Further exper-
imental details are provided elsewhere (11).
Zucker rats were maintained on Purina (St. Louis, MO) 5008 rat
chow (16.7% of total calories from fat). The ZDF/Gmi-fa rat develops
non-insulin-dependent diabetes on this diet. Plasma glucose increased
to 20 mM by week 5 of the study and rose gradually to 40 mM during the
course of the 23-week study. Animals were assigned to either untreated
or treated groups (n  10/group) designated as follows: /fa control (L),
/fa receiving PM (LPM) in drinking water at 2 g/liter, fa/fa control
(F), fa/fa receiving PM (FPM) in drinking water at 2 g/liter, ZDF/
Gmi-fa control (ZDF-Db), and ZDF/Gmi-fa receiving PM (ZDF-DbPM)
in drinking water at 1 g/liter. Plasma glucose in /fa and fa/fa rats was
5 and 8 mM, respectively.
Urine Preparation and Analysis—Rats were housed in metabolic
cages for 24 h to collect urine; urine collection beakers contained several
drops of toluene to prevent microbial growth. Urine samples were
stored at 70 °C, and aliquots of urine from each group of rats were
pooled for analysis. For analyses of NDAPM and FPyPM, either 8 ml of
diabetic or 1.5 ml of non-diabetic urine, containing 1 mg of creatinine,
was adjusted to pH 1 with 6 M HCl and centrifuged (Marathon, Fisher
Scientific) at 2000 rpm for 10 min at 4 °C to remove particulate matter.
The supernatant was then applied to a 60-mg OasisTM MCX column
(Waters), which was washed sequentially with 4 ml each of 0.1 N HCl
and methanol and then eluted with 4 ml of 10% concentrated NH4OH in
methanol. The eluted fractions were dried in vacuo, reconstituted in 1%
HFBA, and ultrafiltered prior to analysis. For analyses of FAPM,
HAPM, PDAPM, and PyPM, aliquots of urine were diluted 1:20 in 1%
HFBA, ultrafiltered as described above, and analyzed directly without
further purification.
PM adducts were quantified using d11-HAPM as the internal stand-
ard, which was added to urine samples prior to sample preparation.
Standard curves were constructed with mixtures of serially diluted
authentic standards and constant amounts of d11-HAPM. Total daily
excretion of PM adducts was calculated using average 24-h urine output
volumes for each animal group: non-DbPM and STZ-DbPM animals,
30 and 145 ml of urine, respectively; LPM, FPM, and ZDF-
DbPM animals, 15, 38, and 158 ml of urine, respectively.
RESULTS
Reaction of PM with PUFAs—We have shown previously
that PM traps intermediates formed during lipid peroxidation
reactions in vitro (10). As an extension of these studies and to
identify additional PM-lipid characteristic of each of these fatty
acids, PM was incubated with either LA or AA in phosphate
buffer at physiological pH for 6 days. Approximately 60% of PM
was consumed in both of the PM-PUFA incubations after 6
days. As shown in Fig. 2, products containing PM were ob-
served in both the LA and AA systems. Product characteriza-
tion, described below, focused on those PM derivatives that
were subsequently detected in the plasma and urine of PM-
treated animals.
Eight PM adducts were observed in the incubation of PM
with LA (Fig. 2A). Six of these (m/z  267, 305, 323, 339, 377,
and 479) had been observed previously, of which two had been
identified, the hexanoate amide HAPM (m/z  267) and the
nonanedioate amide NDAPM (m/z  339) (10). The PM deriv-
ative withm/z 197 has now been identified as the formic acid
amide FAPM, based on MRM-LC/MS/MS analysis of mixing
experiments with authentic standard. The structure of the PM
adducts having m/z  305, 321, 323, 377, and 479, which were
not detected in urine, have not been determined. However, the
product with m/z  479 is consistent with a PM-LA dioxo
derivative, and the products with m/z  323 and 305 are
consistent with a hydrated furan and a furan derivative of PM.
Although formed in different yields than in reactions with
LA, four adducts (FAPM, HAPM, and unknowns with m/z 
305 and 377) were also detected in incubations of PM with AA
(Fig. 2B). Four new compounds were also observed in the
PM-AA incubation. Three of these were identified as pyrrole
(PyPM), formylpyrrole (FPyPM), and pentanedioate (PDAPM)
derivatives of PM, respectively, by MRM-LC/MS/MS analysis
of mixing experiments with authentic standards. None of the
other products in either the LA or AA reactions were detected
in the urine of animals treated with PM, possibly because they
are early or transient intermediates or were labile during urine
collection or storage.
Detection of PM Adducts in Vivo—To determine whether PM
also traps intermediates formed in lipid peroxidation reactions
in vivo, we treated diabetic and obese animals with PM in
drinking water. Urine samples (24 h) were collected at monthly
intervals, and urine pools collected at the 7th month of the
studies were analyzed for PM derivatives. Several compounds
identified in incubations of PM with PUFA in vitro were de-
tected in urine, and in each case, authentic standards were
added to the urines to confirm the presence of the PM adduct in
question by MRM-LC/MS/MS. A typical spiking experiment is
shown in Fig. 3.
Six PM adducts observed in reactions of PM with LA (Fig.
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4A) and AA (Fig. 4B) were also detected in the urine of animals
treated with PM. NDAPM (derived from LA), PDAPM, PyPM,
FPyPM (derived from AA), and FAPM and HAPM (derived
from either PUFA) were readily detected in urine from STZ-
DbPM (Fig. 4C) and FPM (Fig. 4D) animals by MRM-LC/
MS/MS. None of these PM adducts was observed in the urine of
untreated, control animals (data not shown). Other PM deriv-
atives, which have not yet been characterized, were also de-
tected in the urine of PM-treated rats (Fig. 4, C and D), and
each of these products had fragment ions characteristic of PM
when analyzed by daughter-ion LC/MS/MS. Most are more
hydrophobic than PM, which elutes between FAPM and
NDAPM, and may represent products from other lipid (or car-
bohydrate) precursors trapped during PM inhibition of oxida-
tive modification of proteins in vivo.
Quantification of PM Adducts in Vivo—PM adducts in pooled
urine of treated animals were quantified by MRM-LC/MS/MS,
using d11-HAPM as the internal standard. As shown in Fig. 5,
the levels of these adducts in the urine of PM-treated diabetic
animals were on average 5–10-fold higher than those in the
urine of PM-treated non-diabetic animals. FAPM (Fig. 5A),
which may be derived from both LA and AA, was the major
adduct in the urine of control (non-Db) and STZ-Db animals
(22.9  0.8 and 132  12 nmol/24 h, respectively), whereas
PDAPM (Fig. 5A) derived exclusively from AA was the major
product in the urine of Zucker lean (LPM), Zucker obese
(FPM), and Zucker type 2 diabetic (ZDF-Db) rats (9.1  0.2,
68.9  7.0, and 97.0  4.5 nmol/24 h, respectively). Although
FAPM and HAPM were produced in similar yield from both LA
and AA in vitro, FAPM was detected in much larger relative
amounts in urine (Fig. 5, A versus B), suggesting alternative
sources of FAPM in vivo. HAPM excretion (Fig. 5B) was great-
est in STZ-Db animals, about 800 pmol/24 h, and was 10-fold
higher than in the urine of control (non-Db) animals. HAPM
excretion in ZDF-Db animals was also 10-fold higher than in
the urine of lean Zucker rats (L) and 7-fold higher than in the
urine of obese (F) animals. The level of NDAPM (Fig. 5B),
which is produced only from LA peroxidation (or other 9
PUFAs) was typically the lowest of any of the measured ad-
ducts in the urine of animals, averaging about 7 pmol/24 h in
non-diabetic animals and 50–100 pmol/24 h in diabetic ani-
mals. In general, PDAPM, FPyPM, and PyPM, products of AA
oxidation, were more abundant than the LA-derived NDAPM
(Fig. 5), suggesting that despite the higher concentration of LA
in plasma and membrane lipids, AA contributes to the majority
of PM adduct formation in vivo. This is consistent with the
chemistry of these PUFAs, i.e. that AA is more readily oxidized
than LA. Similar results were obtained during Cu2-catalyzed
oxidation of human low density lipoprotein in the presence of
PM (data not shown), i.e. the yield of AA-derived products was
greater than that of LA-derived products, despite the higher
FIG. 2. PM traps intermediates of PUFA peroxidation. PM (1
mM) was incubated with either LA (5 mM) (A) or AA (5 mM) (B) in 200
mM phosphate buffer, pH 7.4, at 37 °C for 6 days. Aliquots of the 6-day
incubations were analyzed by ESI-LC/MS/MS using precursor-ion
scans of m/z  152. Products for which chemical identity has been
established are indicated by letter abbreviations, and products identi-
fied with numbers are not yet characterized. PM adducts marked with
an asterisk were subsequently identified in the urine of animals treated
with PM (see Fig. 4).
FIG. 3. The presence of PM adducts in urine was confirmed by
spiking experiments. Synthetic PM adducts were spiked into urine
samples from PM-treated animals and analyzed by ESI-LC/MS/MS,
using MRM. A representative spiking experiment for verifying the
presence of PDAPM shows a PDAPM standard (A) monitored as 283 
152 and a similar compound identified in the urine of STZ-DbPM rats
(B). A spiking experiment designed to double the peak height of PDAPM
(C) confirmed the presence of PDAPM in the urine sample.
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concentration of LA compared with AA in low density
lipoprotein.
Metabolic Analyses—Plasma glucose and triglyceride levels
in various groups of rats are summarized in Fig. 6. As noted in
several previous studies (11, 12, 17, 18), PM had no effect on
plasma glucose concentrations in any group (Fig. 6A). However,
PM significantly decreased levels of plasma triglycerides in
both STZ-Db and ZDF animals (Fig. 6B) by 50 and 35%,
respectively, although the effects on hyperlipidemia in the
obese rats, when fed a high fat diet (used to induce diabetes in
the ZDF rat), were not statistically significant. Both groups of
diabetic rats had dramatically lower levels of plasma triglycer-
ides but higher levels of PM adducts (Fig. 5) compared with
non-diabetic obese (F) rats, suggesting a role for diabetes in the
enhancement of lipid peroxidation reactions (discussed below).
DISCUSSION
Summary—The goal of this study was to evaluate the role of
PM as an inhibitor of lipoxidation reactions in obese and dia-
betic animals and thereby to gain a better understanding of the
role of lipoxidation chemistry in the development of renal dis-
ease in diabetes. In preparatory studies, we identified 12 PM
derivatives that were formed during incubation of PM with LA
or AA under peroxidizing conditions in vitro. We then admin-
istered PM to type 1 and type 2 diabetic rats, to obese hyper-
lipidemic rats, and to lean controls, and chemically character-
ized the six PM derivatives that were detected in the plasma
and urine of animals treated with PM. The elevated levels of
PM adducts in the urine of diabetic and hyperlipidemic rats
suggested that there was increased lipid peroxidation in these
animals and that the protective effects of PM were consistent
with its lipid-lowering activity and proposed role as an AGE/
ALE inhibitor and chemical trap for intermediates in lipoxida-
tion reactions.
Mechanism of Action of PM—Radical and hydroperoxide in-
termediates in lipid peroxidation reactions decompose to reac-
tive carbonyl compounds, such as -keto acids, -ketoalde-
hydes, and -hydroxyaldehydes (19, 20). The two most
abundant adducts detected in incubations of PM with peroxi-
dizing LA or AA were FAPM and HAPM. We had proposed
previously (10) that HAPM was formed by reaction of PM with
13-oxo-9,11-octadecadienoic acid (13-keto-octadecadienoic acid
(13-KODE)), an intermediate in peroxidation of LA (and also
from the analogous product of peroxidation of AA and other 6
FIG. 4. PM adducts identified in vitro and in vivo. PM adducts
were analyzed by MRM-LC/MS/MS in reactions of PM with PUFAs and
in the urine of animals treated with PM. Shown are total ion currents
of six MRM channels: FAPM (197  152), HAPM (267  152), NDAPM
(339  152), PDAPM (283  152), PyPM (219  152), and FPyPM
(247  152). FAPM and HAPM were found in reactions of PM with LA
(A) and AA (B). NDAPM is unique to the LA reaction (A), whereas
PDAPM, FPyPM, and PyPM are found only in the AA reaction (B).
Analysis of STZ-DbPM urine (C) and FPM urine (D) revealed that
all of these PM adducts were found in the urine of animals treated with
PM.
FIG. 5. Quantification of PM adducts in the urine of treated
animals. PM adducts were quantified in urine pools by ESI-LC/MS/
MS, using MRM with d11-HAPM as the internal standard. FAPM,
PDAPM, and PyPM (A) were quantitatively the major adducts detected
in the urine of PM-treated animals. Amounts of HAPM, NDAPM, and
FPyPM (B) were generally 	1 nmol/24 h. Data are mean  S.D. *, p 	
0.001 versus non-DbPM; #, p 	 0.001 versus LPM; $, p 	 0.001
versus FPM. One-way analysis of variance with Tukey-Kramer’s post
test was performed using GraphPad (San Diego, CA) InStat version
3.05 for Windows.
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PUFAs). In that scheme, PM added to the 13-carbon of 13-keto-
octadecadienoic acid, and HAPM was released on oxidative
cleavage of the 12–13 carbon-carbon bond. NDAPM and
PDAPMwould be formed in an analogous manner by adduction
of PM to the 9- and 5-keto-octadecadienoic acids formed from
LA and AA, respectively. However, although this scheme ex-
plained the formation of HAPM, NDAPM, and PDAPM, it did
not account for the formation of one of the major products, the
formyl adduct FAPM, nor have we been able to detect in in vitro
reactions the putative oxidative cleavage products from the
other ends of the lipid molecule. The present data, which iden-
tify FAPM as a major product formed during lipid peroxidation
reactions in the presence of PM, suggest an alternative mech-
anism of action of PM (Scheme 1). In this scheme, the conju-
gated diene hydroperoxides decompose oxidatively to ketoalde-
hydes, which then may react with the primary amine and
phenoxyl groups of PM to form a transient, seven-membered
ring that undergoes a ring-opening rearrangement to form
mixed amide and hemiacetal adducts to PM. The hemiacetals
hydrolyze in aqueous solution to yield stable amide adducts,
depending on the manner of addition of PM to the ketoalde-
hyde. This mechanism has been confirmed, in part, by detec-
tion of acetyl and benzoyl amide derivatives of PM in reactions
of PM with the model dicarbonyl compound phenylpropanedi-
one.2 The tertiary amine products FPyPM and PyPM are most
likely formed by reaction of the primary amine of PM with
1,4-dioxo intermediates from the interior of AA.
One of the unexpected observations from both the in vitro
and in vivo studies was that no PM adducts analogous to classic
AGE/ALEs were detected. Modification of protein during lipid
peroxidation reactions produces characteristic lysine AGE/
ALEs, such as N-(carboxymethyl)lysine, N-(carboxyethyl)ly-
sine, and the malondialdehyde and 2-hydroxynonenal adducts,
malondialdehyde-lysine and 4-hydroxy-2-nonenal-lysine (10,
21). However, we were unable to detect even traces of the
analogous N-carboxymethyl-PM, N-carboxyethyl-PM, or the
malondialdehyde or 4-hydroxy-2-nonenal adducts to PM, based
on MRM-LC/MS/MS analyses, either in vitro or in vivo. Indeed,
although PM is a powerful inhibitor of AGE/ALE formation, it
actually exhibits low reactivity toward small dicarbonyl com-
pounds such as glyoxal (GO), methylglyoxal (MGO), and ma-
londialdehyde under physiological conditions (5, 22, 23).
Voziyan et al. (23) isolated and characterized a stable 5-ring
adduct between PM and GO, glyoxal-PM (GOPM), in incuba-
tions of PM with GO at equimolar and high concentration (10
mM each PM and GO). However, GOPM was not detectable in
vivo nor in incubations of PM and GO at micromolar concen-
trations in vitro in the range of typical plasma concentrations
of these compounds in PM-treated rats. Our in vivo data, com-
bined with evidence that PM prevents the formation of char-
acteristic ALEs on protein without forming the corresponding
PM derivatives (10), suggest that the immediate precursors of
these AGEs, such as GO, MGO, malondialdehyde, and 4-hy-
droxy-2-nonenal, are not formed. Rather, PM appears to trap
earlier, as yet unidentified, diketone or ketoaldehyde interme-
diates in peroxidation of PUFAs before they decompose to the
more reactive carbonyl and dicarbonyl compounds.
Formation of PM Adducts ex Vivo—In control experiments,
to exclude the possibility that some adducts might be formed
during the urine collection process, PM was added to the urine
of untreated control, obese, and diabetic animals and allowed to
incubate for 24 h at room temperature. Under these conditions,
with the exception of FPyPM, 	10% of the PM adducts recov-
ered in urine was formed ex vivo. (The yield of FPyPM ac-
counted for up to 50% of the amount recovered in the urine of
PM-treated rats.) These experiments establish that some reac-
tive lipoxidation intermediates are excreted in urine, probably
in the form of polar lipid derivatives. However, all six of the PM
adducts identified in urine were also detected in fresh frozen
plasma samples from PM-treated animals in approximately the
same ratio as they appeared in urine, indicating that the ad-
ducts were indeed formed in vivo. Newman et al. (24) have
reported the urinary excretion of isomers of the dihydroxy and
epoxy forms of AA, indicating that these more polar molecules
are readily soluble in urine. Thus, early oxidation products of
PUFA may be further oxidized during the standing of urine at
room temperature forming reactive carbonyl intermediates,
which would then react with PM. Incubation of PM with urine
from diabetic and hyperlipidemic patients may prove useful as
a diagnostic test to assess the oxidative state of plasma in
diabetes, based on the amount of PM adducts formed during ex
vivo incubation with urine. Uremia also enhances production of
AGE/ALEs in plasma and tissues (25), possibly the result of
carbonyl stress (26), and PM may also prove useful for identi-
fication of reactive carbonyl toxins and AGE/ALE precursors in
uremic plasma.
The Interplay between Hyperglycemia and Hyperlipidemia—
2 T. O. Metz, M. L. Stroman, S. R. Thorpe, and J. W. Baynes, manu-
script in preparation.
FIG. 6. Plasma glucose and plasma triglycerides. PM had no
effect on plasma glucose concentrations (A) in treated animals, whereas
it caused a 50 and 35% reduction in plasma triglycerides (B) of STZ-
DbPM and ZDF-DbPM animals, respectively. PM had no significant
effect on plasma triglycerides in FPM animals. Data are means S.E.
*, p 0.05 versus STZ-Db; #, p 0.05 versus ZDF-Db. One-way analysis
of variance with Tukey-Kramer’s post test was performed using Graph-
Pad InStat version 3.05 for Windows.
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Although the mechanism by which PM causes a reduction in
triglycerides (and cholesterol) in STZ-Db and fa/fa rats (11, 12)
is unknown, protection against kidney disease may result from
both inhibition of hyperlipidemia and trapping of intermedi-
ates in formation of AGE/ALEs. Although both mechanisms
may be operative, it is clear that PM acts at least in part as a
trap for intermediates in the lipoxidative modification of pro-
teins (Figs. 4 and 5), documenting for the first time the pro-
posed mechanism of action of an AGE or ALE inhibitor in vivo.
At the conclusion of this study, the relative role of hypergly-
cemia versus hyperlipidemia in the chemical modification of
proteins and the pathogenesis of diabetic complications still
remains uncertain. The fact that several biomarkers of protein
modification, such as N-(carboxymethyl)lysine and N-(car-
boxyethyl)lysine, can be derived from either sugar or lipid
sources complicates the interpretation of analytical data. Our
results suggest, however, that lipids may be the primary source
of chemical modification of proteins in diabetes and obesity (11,
12), especially in the presence of hyperlipidemia or dyslipi-
demia. Thus, in all of the hyperlipidemic animals, including the
non-diabetic fa/fa rat, there was a substantial increase in the
urinary excretion of PM adducts derived from LA and AA,
suggesting an increase in lipid peroxidation. There was also an
indication that concurrent hyperglycemia exacerbated lipoxi-
dative modification of protein. This argument is based on the
comparison of levels of PM adducts recovered in the urine of the
various animal models. The level of PM adducts were, in gen-
eral, 2–4-fold higher in both STZ-DbPM and ZDF-DbPM
animals than in non-diabetic obese FPM animals (Fig. 5),
despite dramatically higher levels of triglycerides and lipemia
in the obese animals (Fig. 6). Thus, it appears that although
severe hyperlipidemia may be sufficient to induce lipoxidative
damage, hyperlipidemia, combined with hyperglycemia and
possibly an increase in oxidative stress in diabetes (27), may
exacerbate the chemical modification of proteins by lipids in
diabetes.
In conclusion, although the focus of these studies has been on
the mechanism of action of PM, the broader implications of the
work suggest a major role for lipid peroxidation and lipoxida-
tive modification of proteins in the development of chronic
complications in diabetes. These studies provide a mechanistic
explanation for the results of recent clinical trials that have
identified plasma triglyceride concentration as an independent
risk factor for development of retinal (28), renal, and cardio-
vascular disease in both type 1 and type 2 diabetes (29–31) and
in non-diabetic populations (32, 33). They also lend support to
the current emphasis on more aggressive control of dyslipi-
demia in diabetes (34, 35).
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